Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Autor: H Miles Prince, Youn H Kim, Steven M Horwitz, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, Jose A Sanches, Pablo L Ortiz-Romero, Oleg E Akilov, Larisa Geskin, Judith Trotman, Kerry Taylor, Stephane Dalle, Michael Weichenthal, Jan Walewski, David Fisher, Brigitte Dréno, Rudolf Stadler, Tatyana Feldman, Timothy M Kuzel, Yinghui Wang, Maria Corinna Palanca-Wessels, Erin Zagadailov, William L Trepicchio, Wenwen Zhang, Hui-Min Lin, Yi Liu, Dirk Huebner, Meredith Little, Sean Whittaker, Madeleine Duvic, David Joske, H. Miles Prince, Ian D. Lewis, Constanze Jonak, Franz Trautinger, Oliver Bechter, Dominique Bron, Vladmir Claudio C. de Lima, Jose Antonio Sanches, Richard Klasa, Martine Bagot, Marie Beylot-Barry, Michel D'Incan, Brigitte Dreno, Florent Grange, Jan Nicolay, Marion Wobser, Chalid Assaf, Carmen Loquai, Michele Spina, Alberto Bosi, Pier Paolo Fattori, Aleksandra Grzanka, Andres Lopez-Hernandez, Pablo L. Ortiz-Romero, Jose Juan Rifon Roca, Silvana Novelli Canales, Timothy Illidge, Rod Johnson, Stephen Morris, Pam McKay, Oleg Akilov, Steve Horwitz, Youn H. Kim, Barbara Pro, Timothy Kuzel, Adam Lerner, Herbert Eradat, Lubomir Sokol, David C. Fisher, Sarah Hughey

Publikováno v: The Lancet. 390:555-566

Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce0ee405e66e583edbdaab74473710c
https://doi.org/10.1016/s0140-6736(17)31266-7

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Autor: S. Martin Shreeve, Peter Johnson, Andres Lopez-Hernandez, Ulrich Dührsen, Jun Zhu, Laurie H. Sehn, Catherine Thieblemont, Wyndham H. Wilson, Steven Sun, Jodi Carey, Olga Samoilova, Itaru Matsumura, Jessica Vermeulen, Louis M. Staudt, Anas Younes, Xiaonan Hong, Pier Luigi Zinzani, Cheolwon Suh, Grace Liu

Publikováno v: Blood. 132:784-784

Introduction DLBCL is an aggressive disease that can be classified by immunohistochemistry (IHC) into GCB and non-GCB or by gene expression profiling (GEP) into GCB, activated B-cell (ABC), and unclassified subtypes. RCHOP is the standard frontline t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46253a43020bae854f8f4a8773c637d
https://doi.org/10.1182/blood-2018-99-112988

Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome

Autor: Roser Solans-Laqué, Mercedes Campillo, Andrés Palacios, Miquel Vilardell-Tarrés, Andres Lopez-Hernandez, Bosch-Gil Ja

Publikováno v: Seminars in arthritis and rheumatism. 41(3)

Objective To assess the risk and predictors of lymphoma development in a large cohort of patients with primary Sjogren's syndrome (pSS). Methods Cox-regression analyses were used to study the predictive value of clinical and laboratory findings at pS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7795d6926d19a1d4f2fdd1ac858a207
https://pubmed.ncbi.nlm.nih.gov/21665245